Targeting the neural cell adhesion molecule in cancer

被引：71
作者：
Jensen, Markus
Berthold, Frank
机构：
[1] Univ Cologne, Dept Paediat Oncol & Hematol, D-50924 Cologne, Germany
[2] Univ Cologne, Ctr Mol Med Cologne, Cologne, Germany
来源：
CANCER LETTERS | 2007年 / 258卷 / 01期
关键词：
neural cell adhesion molecule; NCAM; tumour targeting; monoclonal antibodies; immunotherapy;
D O I：
10.1016/j.canlet.2007.09.004
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
NCAM is a tumour associated antigen expressed on small cell lung cancer, neuroblastoma, rhabdomyosarkoma, brain tumours, multiple myelomas and acute myeloid leukaemia. Constant and strong expression of NCAM is a prerequisite for the development of antibody-based immunotherapies. From the spectrum of existing anti-NCAM compounds, radioimmunoconjugates and immunotoxins represent the clinically most advanced and successful strategies. Here we provide an overview of the evolving field of anti-NCAM immunotherapy for cancer and discuss its indications and limitations. (c) 2007 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码：9 / 21
页数：13
相关论文
共 91 条
[21]  
Hall H, 1997, J NEUROCHEM, V68, P544
[22]   Tyrosine and serine phosphorylation of the neural cell adhesion molecule L1 is implicated in its oligomannosidic glycan dependent association with NCAM and neurite outgrowth [J].
Heiland, PC ;
Griffith, LS ;
Lange, R ;
Schachner, M ;
Hertlein, B ;
Traub, O ;
Schmitz, B .
EUROPEAN JOURNAL OF CELL BIOLOGY, 1998, 75 (02) :97-106
[23]   Immunotherapy of malignant ascites with trifunctional antibodies [J].
Heiss, MM ;
Ströhlein, MA ;
Jäger, M ;
Kimmig, R ;
Burges, A ;
Schoberth, A ;
Jauch, KW ;
Schildberg, FW ;
Lindhofer, H .
INTERNATIONAL JOURNAL OF CANCER, 2005, 117 (03) :435-443
[24]  
Hikawa T, 2000, J EXP CLIN CANC RES, V19, P357
[25]   QUANTITATIVE DISTRIBUTION OF CLUSTER-1 SMALL CELL LUNG-CANCER ANTIGEN IN CANCEROUS AND NON-CANCEROUS TISSUES, CULTURED-CELLS AND SERA [J].
HIRANO, T ;
HIROHASHI, S ;
KUNII, T ;
NOGUCHI, M ;
SHIMOSATO, Y ;
HAYATA, Y .
JAPANESE JOURNAL OF CANCER RESEARCH, 1989, 80 (04) :348-355
[26]   A model to estimate the dose to tumour following intracavity administration of radioimmunoconjugates to patients with malignant gliomas [J].
Hopkins, K ;
Papanastassiou, V ;
Zananiri, FAF ;
Kemshead, JT .
BRITISH JOURNAL OF RADIOLOGY, 1997, 70 (839) :1152-1161
[27]   A PILOT-STUDY OF THE TREATMENT OF PATIENTS WITH RECURRENT MALIGNANT GLIOMAS WITH INTRATUMORAL Y-90 RADIOIMMUNOCONJUGATES [J].
HOPKINS, K ;
CHANDLER, C ;
BULLIMORE, J ;
SANDEMAN, D ;
COAKHAM, H ;
KEMSHEAD, JT .
RADIOTHERAPY AND ONCOLOGY, 1995, 34 (02) :121-131
[28]   Direct injection of 90Y MoAbs into glioma tumor resection cavities leads to limited diffusion of the radioimmunoconjugates into normal brain parenchyma:: A model to estimate absorbed radiation dose [J].
Hopkins, K ;
Chandler, C ;
Eatough, J ;
Moss, T ;
Kemshead, JT .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1998, 40 (04) :835-844
[29]  
Hosono M, 1999, J NUCL MED, V40, P1216
[30]  
HOSONO MN, 1994, J NUCL MED, V35, P504
12345678910